Does herbal medicine reduce the risk of hepatocellular carcinoma?
Does herbal medicine reduce the risk of hepatocellular carcinoma?
复制标题
DOI：
10.3748/wjg.v21.i37.10598
复制
发表时间：
2015-10-07
影响因子：
4.3
通讯作者：
Yamamoto, Naoto
中科院分区：
文献类型：
--
作者：
Rino, Yasushi;Yukawa, Norio;Yamamoto, Naoto
许多草药是有效的抗炎剂，因此可以抑制肝细胞癌（HCC）的发展。最近，在对既往干扰素治疗无应答的丙型肝炎病毒基因型1感染患者中，使用含有ledipasvir和sofosbuvir的单片剂方案治疗导致持续病毒学应答率较高。预计慢性丙型肝炎患者将在全球范围内接受这种治疗。然而，许多患者有肝炎样脂肪肝和非酒精性脂肪性肝炎。迫切需要一种预防这一亚组患者发生HCC的策略。草药是否可以抑制HCC的发展仍有待确定。然而，草药是有效的抗炎剂，可以抑制HCC的发展。因此，有必要进行临床试验，探索草药在预防和治疗肝癌方面的有效性。目前缺乏知识和教育计划是增加使用潜在有效的草药和进行前瞻性临床试验的障碍。
Many herbal medicines are effective anti-inflammatory agents and may therefore suppress the development of hepatocellular carcinoma (HCC). Recently, treatment with a single-tablet regimen containing ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with hepatitis C virus genotype 1 infection who did not respond to prior interferon-based treatment. Patients with chronic hepatitis C are expected to receive this treatment worldwide. However, many patients have hepatitis-like fatty liver and nonalcoholic steatohepatitis. A strategy to prevent the development of HCC in this subgroup of patients is urgently required. Whether herbal medicines can suppress the development of HCC remains to be established. However, herbal medicines are effective anti-inflammatory agents and may inhibit the development of HCC. Clinical trials exploring the effectiveness of herbal medicines in the prevention and treatment of HCC are therefore warranted. The current lack of knowledge and of educational programs is a barrier to increasing the use of potentially effective herbal medicines and performing prospective clinical trials.